Phase 2 Trial Compares Cabazitaxel and ARPIs in Poor-Prognosis mCRPC After Docetaxel
/in Clinical Trial, Metastatic, Phase 2/by MaxLUNAR Trial Shows Combination Therapy Doubles Progression-Free Survival in Recurrent Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxASPIRE Trial Explores Early Chemotherapy Addition for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC
/in Clinical Trial, Metastatic/by MaxEfficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxAZD6621: A T-Cell Therapy Targets Hidden Prostate Cancer Driver
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2: Tulmimetostat + ARPI Combo for mHSPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026